Functional Assay Platforms for Drug Screening and Toxicology
Accurate characterization of cellular responses to experimental compounds or gene modulation requires robust and validated assay platforms. This service provides custom development of ELISA and cell-based assays designed to measure key cellular phenotypes such as viability, proliferation, cytotoxicity, and cell cycle distribution. These assays are critical components of pharmacological profiling, RNAi validation, mechanistic research, and preclinical toxicology testing. By integrating molecular readouts with functional endpoints, this service supports high-resolution analysis of compound efficacy and safety.
ELISA Assay Development and Quantitative Protein Analysis
Enzyme-linked immunosorbent assays (ELISA) enable precise quantification of proteins secreted or expressed in response to treatment or genetic manipulation. Custom sandwich or competitive ELISA formats are developed to detect cytokines, growth factors, apoptotic markers, phosphorylated proteins, or metabolic regulators in cell culture supernatants or lysates. Antibody pairs are screened and optimized for specificity, signal-to-noise ratio, and linear dynamic range. Colorimetric, fluorescent, or chemiluminescent detection systems are tailored to sensitivity requirements and plate reader compatibility. Assays can be developed for endpoint or kinetic measurements depending on the biological process of interest.
Viability and Cytotoxicity Assays
Cell viability assays provide a direct measure of cell health, proliferation, or death in response to compound exposure. These assays are essential for determining IC50 values, therapeutic windows, and toxicological thresholds. Common platforms include ATP quantification (CellTiter-Glo), NADH-based metabolic activity (MTT, XTT, WST-1), and membrane integrity assays using dyes such as propidium iodide or SYTOX Green. For live-cell applications, real-time imaging and fluorescence tracking are employed to capture dynamic cell responses. All assays are optimized for reproducibility, low background, and scalability to 96-well or 384-well formats.
Cell Cycle Analysis and Checkpoint Modulation
Cell-based assays for cell cycle progression provide detailed information on how treatments influence mitotic checkpoints, DNA replication, and apoptosis. Flow cytometry-based DNA content analysis using propidium iodide or DAPI allows quantification of G0/G1, S, and G2/M phases. BrdU or EdU incorporation assays are used to monitor DNA synthesis during S-phase. Custom panels include detection of cell cycle regulators such as cyclins, CDKs, p21, p27, and phosphorylated histone H3. These assays are critical for evaluating mechanisms of action for anticancer agents and identifying cell cycle arrest induced by RNAi or gene editing.
High-Throughput Screening and Multiplexing Options
Assays are designed to accommodate high-throughput screening (HTS) of chemical libraries, biologics, or gene silencing reagents. Miniaturization and automation compatibility enable large-scale screening campaigns with minimal reagent use and high data output. Multiplexed assays combine viability, apoptosis, and cell cycle markers in a single readout to reduce variability and increase biological resolution. Integrated data pipelines are available for normalization, statistical analysis, and visualization of complex datasets.
Customization, Validation, and Regulatory Readiness
All assay platforms are tailored to the client’s target pathways, treatment regimens, and model systems. Assay validation includes determination of sensitivity, limit of detection, inter-assay and intra-assay precision, and dynamic range. Where applicable, GLP-compatible protocols are available for studies that support IND-enabling pharmacology or toxicology submissions. Detailed documentation, raw data files, and analysis summaries are provided for inclusion in regulatory filings or scientific publications.
Altogen Labs Assay Development Expertise
Altogen Labs offers custom ELISA and cell-based assay development services that integrate functional biology with quantitative molecular detection. Their team specializes in adapting assays for use in both in vitro and in vivo contexts, with expertise in oncology, immunology, and toxicology. Whether supporting early discovery or regulatory preclinical studies, these services are designed to deliver reproducible, high-content data with translational value.